Dr. Paul Nunzio DeSantis, Pharm.D

Event-driven, research analyst, hedge fund analyst, biotech
Dr. Paul Nunzio DeSantis, Pharm.D
Event-driven, research analyst, hedge fund analyst, biotech
Contributor since: 2014
Company: Alpha BioPharma Advisers
12/9/14
Dr. Paul Nunzio DeSantis, Pharm.D
GBIM: Technical Move Confirms Breakout Today $GBIM http://seekingalpha.com/p/23uwn
11/19/14
Dr. Paul Nunzio DeSantis, Pharm.D
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of... $CLVS http://seekingalpha.com/a/1lrrt
11/12/14
Dr. Paul Nunzio DeSantis, Pharm.D
Achillion Pharmaceuticals: Still Bullish, But Taking Profits $ACHN http://seekingalpha.com/a/1lcdn
10/30/14
Dr. Paul Nunzio DeSantis, Pharm.D
INCY: GREAT QUARTER, STILL SEE LONG TERM UPSIDE TO $93, BUT BOOKING SOME PROFITS HERE $INCY http://seekingalpha.com/p/216mj
10/28/14
Dr. Paul Nunzio DeSantis, Pharm.D
Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction... $INSIF http://seekingalpha.com/a/1jsgl
10/2/14
Dr. Paul Nunzio DeSantis, Pharm.D
Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder $ACHN http://seekingalpha.com/a/1ido9
9/11/14
Dr. Paul Nunzio DeSantis, Pharm.D
Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93,... $INCY http://seekingalpha.com/a/1hbjh
8/12/14
Dr. Paul Nunzio DeSantis, Pharm.D
PSivida Corp (PSDV): Imminent New Drug Approval, Steady News Flow, & Tethadur Partnership Raising... $PSDV http://seekingalpha.com/a/1fr4n
7/24/14
Dr. Paul Nunzio DeSantis, Pharm.D
$4.1B Sovaldi Sales Est. Wrong, Heres Why, We Think $GILD http://seekingalpha.com/p/1uc0h
7/24/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year $GILD http://seekingalpha.com/a/1e3yx
7/22/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead Sciences Should Report $4B In Sovaldi Sales In Q2'14 $GILD http://seekingalpha.com/a/1dyjn
7/22/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead's Pipeline Requires MacroGenics' ImmunoOncology Platform (M&A) $MGNX http://seekingalpha.com/a/1dy4d
7/18/14
Dr. Paul Nunzio DeSantis, Pharm.D
Sovaldi And GILD 2Q $4.1B Possible, $3.5B Minimum $GILD http://seekingalpha.com/p/1tyo7
If GILD's quarterly earnings are anywhere near $4B -- that number will be rocket fuel for the shares. October will be the acid test imo.
I have my full allotment but $4B -- I'll be back accumulating shares. I'm bullish on GILD but I have to see that number to be convinced.
7/14/14
Dr. Paul Nunzio DeSantis, Pharm.D
Shire (SHPG) Bid Came In As Expected $ABBV, $SHPG http://seekingalpha.com/p/1tnl1
Well, Ireland is 'Green' for more reasons than rain -- 12.5% corporate tax rate! No wonder ABBV believes the 'grass is greener' there.
Right?! I'd be looking for a lucky charm if I was a US Pharma company too
7/7/14
Dr. Paul Nunzio DeSantis, Pharm.D
GREAT POINT PARTNERS LLC Files 13-G On Oncogenex (OGXI) $OGXI http://seekingalpha.com/p/1tarx
7/9/14
sounds like good
6/30/14
Dr. Paul Nunzio DeSantis, Pharm.D
Consider Shire Pharmaceuticals Now; +20% Upside Left In Takeover Bid By Abbvie $SHPG http://seekingalpha.com/a/1d533
6/10/14
Dr. Paul Nunzio DeSantis, Pharm.D
Merck's Acquisition Of Idenix Pharmaceuticals Is An Admission Of Inferiority To Sovaldi Regimens $GILD http://seekingalpha.com/a/1chmb
5/13/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead Going To Buy Macrogenics (MGNX) Over Next 2 Years http://seekingalpha.com/p/1qehf
4/29/14
Dr. Paul Nunzio DeSantis, Pharm.D
Tweet Of The Week On Gilead: Carl Icahn Entering Gilead? $GILD http://seekingalpha.com/p/1pn1n
4/28/14
Dr. Paul Nunzio DeSantis, Pharm.D
OncoGenex: Phase 3 Trial In First Line Metastatic Prostate Cancer Fails, Now What? $OGXI http://seekingalpha.com/a/1aiqn
4/23/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead: X-Marks The Spot For Sovaldi Sales $GILD http://seekingalpha.com/a/1a88v
4/14/14
Dr. Paul Nunzio DeSantis, Pharm.D
Intercept Pharmaceuticals (Part IIa) - Quick Takeaways On OCA From EASL Abstracts And Presentations $ICPT http://seekingalpha.com/a/19uy9
4/11/14
Dr. Paul Nunzio DeSantis, Pharm.D
Intercept Pharmaceuticals (Part II): The Short Story Is Over, Time For The Long Story $ICPT http://seekingalpha.com/a/19r5v
11/7/14
Hi Dr. Paul Nunzio DeSantis, what's your take on the ICPT new FLINT results?
2/25/14
Dr. Paul Nunzio DeSantis, Pharm.D
Chelsea Therapeutics: Caution Warranted $CHTP http://seekingalpha.com/a/17s4x
2/24/14
Dr. Paul Nunzio DeSantis, Pharm.D
A Picture Is Worth A Thousand Words: Implications From Sovaldi Treatment Trends $GILD http://seekingalpha.com/a/17tab
2/18/14
Dr. Paul Nunzio DeSantis, Pharm.D
PSivida: Positive Roche And Regeneron Conference Calls Confirm Tehadur's Potential $PSDV http://seekingalpha.com/a/17f53
2/15/14
Dr. Paul Nunzio DeSantis, Pharm.D
Pioneer Natural Resources: A Deep Dive Suggests Possible M&A Upside $PXD http://seekingalpha.com/a/17cdx
2/5/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead: A Solid 2014 Outlook Still Looks Conservative; Strong Buy $GILD http://seekingalpha.com/a/16r6l
2/6/14
So why's it down 5 bucks?????
2/6/14
buy the rumor sell the news could explain this pullback. I am remaining long.
2/4/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead: Patient Checkup (Earnings Preview) $GILD http://seekingalpha.com/a/16poz
1/22/14
Dr. Paul Nunzio DeSantis, Pharm.D
Gilead: The Rising Tide Is Coming $GILD http://seekingalpha.com/a/15ze1
1/14/14
Dr. Paul Nunzio DeSantis, Pharm.D
The Short Story Of Intercept Pharmaceutical's (Part I): A Conference Call With Expert Physicians $ICPT http://seekingalpha.com/a/15mfx
1/6/14
Dr. Paul Nunzio DeSantis, Pharm.D